S&P ASX All Technology

3,893.00

0.20%

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

BC43

Inter-amer 30 (BC43)

Inter-amer 30

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:BC43

1 2 Next >>

Date	Time	Source	Headline	Symbol	Company
14/11/2002	01:09	UK Regulatory	Rebecca O. Kendall Announces Retirement; Robert A. Armitage Promoted to Lilly Senior Vice President, General Counsel	LSE:BC43	Inter-amer 30
09/11/2002	20:30	UK Regulatory	Eli Lilly and Company	LSE:BC43	Inter-amer 30
08/11/2002	23:30	UK Regulatory	Lilly Outlines to Wall Street Its Strategy To Realize Its Growth Opportunities and Deliver Superior Earnings Growth Over the Lon	LSE:BC43	Inter-amer 30
08/11/2002	18:19	UK Regulatory	Eli Lilly and Company	LSE:BC43	Inter-amer 30
08/11/2002	05:08	UK Regulatory	Eli Lilly and Company	LSE:BC43	Inter-amer 30
06/11/2002	03:02	UK Regulatory	Eli Lilly and Company	LSE:BC43	Inter-amer 30
02/11/2002	00:47	UK Regulatory	Eli Lilly and Company	LSE:BC43	Inter-amer 30
31/10/2002	02:03	UK Regulatory	Eli Lilly and Company	LSE:BC43	Inter-amer 30
30/10/2002	01:00	UK Regulatory	Cymbalta Data Suggest Rapid and Sustained Response by First Week of Therapy	LSE:BC43	Inter-amer 30
23/10/2002	22:10	UK Regulatory	3rd Quarter Results	LSE:BC43	Inter-amer 30
22/10/2002	17:01	UK Regulatory	Alimta Continues To Show Versatility in Treating Different Cancers	LSE:BC43	Inter-amer 30
22/10/2002	06:15	UK Regulatory	Dividend Declaration	LSE:BC43	Inter-amer 30
18/10/2002	17:00	UK Regulatory	Combining Innovative Therapies for Optimal Cancer Care; Effectiveness of Gemzar-Based Combination Regimens is Topic of Workshop	LSE:BC43	Inter-amer 30
02/10/2002	00:10	UK Regulatory	Newly Published Study Demonstrates Sustained Efficacy of Evista -raloxifene HCl- in Reducing Risk of Spinal Fractures	LSE:BC43	Inter-amer 30
26/09/2002	07:59	UK Regulatory	Lilly Asserts The New England Journal of Medicine ``Sounding Board'' Opinion Article Attempts to Turn Back the Clock on Care of	LSE:BC43	Inter-amer 30
25/09/2002	07:39	UK Regulatory	Re Alliance	LSE:BC43	Inter-amer 30
24/09/2002	10:05	UK Regulatory	Re Alliance	LSE:BC43	Inter-amer 30
20/09/2002	23:07	UK Regulatory	Statement re	LSE:BC43	Inter-amer 30
18/09/2002	00:34	UK Regulatory	Lilly Launches World's Largest Severe Sepsis Clinical Trial; 11,000 Patients to be Enrolled in Study of Xigris Use in Patients w	LSE:BC43	Inter-amer 30
17/09/2002	03:02	UK Regulatory	FDA Issues Approvable Letter for Lilly's Cymbalta for Treatment of Depression; From the Makers of Prozac, Cymbalta Will Offer Ne	LSE:BC43	Inter-amer 30
17/09/2002	00:04	UK Regulatory	Miscellaneous	LSE:BC43	Inter-amer 30
04/09/2002	00:08	UK Regulatory	Tadalafil for the Treatment of Erectile Dysfunction Receives Positive Recommendation From the Australian Drug Evaluation Committ	LSE:BC43	Inter-amer 30
27/08/2002	05:11	UK Regulatory	Regulatory Approval	LSE:BC43	Inter-amer 30
27/08/2002	01:44	UK Regulatory	Miscellaneous	LSE:BC43	Inter-amer 30
15/08/2002	05:02	UK Regulatory	Miscellaneous	LSE:BC43	Inter-amer 30
15/08/2002	02:56	UK Regulatory	Miscellaneous	LSE:BC43	Inter-amer 30
14/08/2002	23:29	UK Regulatory	FDA Issues Approvable Letter for Strattera for ADHD; Strattera Would Give Patients, Families and Physicians a New Treatment Opti	LSE:BC43	Inter-amer 30
01/08/2002	17:23	UK Regulatory	Lilly's Xigris Becomes First and Only Medical Product Approved for BIPA Payment in Medicare Patients	LSE:BC43	Inter-amer 30
31/07/2002	00:50	UK Regulatory	Re Alliance	LSE:BC43	Inter-amer 30
26/07/2002	06:03	UK Regulatory	Lilly ICOS LLC	LSE:BC43	Inter-amer 30